The H3K27 histone N-methyltransferase EZH2 is a pusher of EMT leading to TKIs resistance, and its inhibitors may contribute to re-sensitize tumor to antiangiogenic treatment, which has been proven in preclinical test in RCC lines (Wagener et al., 2008; Adelaiye et al., 2015). Here, EZH2 is linked to neoplasm.